Taken together, these studies emphasize a mechanism for the anti-tumor activity observed for pharmacological MDM2 inhibition in TNBC independent of p53 function and stresses its therapeutic potential in this breast cancer subtype in the presence of inactivating p53 mutations. The gene discussed is TP53; the disease is breast carcinoma.